Jeon Yejoo, Kim Haeryoung, Jang Eun Sun, Hong Sukho, Kim Jin Wook, Yoon Yoo-Seok, Cho Jai Young, Han Ho-Seong, Jeong Sook-Hyang
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
APMIS. 2016 Mar;124(3):208-15. doi: 10.1111/apm.12491. Epub 2016 Jan 13.
Hepatocellular carcinoma (HCC) patients commonly experience poor overall survival (OS) and disease-free survival (DFS) after curative surgical resection. Glypican-3 (GPC3) has been suggested as a prognostic biomarker for post-operative survival. However, few to none of these studies have included South Korean patients. This study aimed to determine GPC3 expression rate, clinical correlation, and post-operative prognostic value in South Korean HCC patients who underwent curative surgical resection. Surgically resected tissues from 185 HCC patients were collected and assembled into tissue microarrays (TMAs), which were stained for GPC3 by immunohistochemistry. GPC3 expression rates were correlated with clinicopathological information, and survival analyses were performed to assess the prognostic value of GPC3. GPC3 expression was present in 153 patients (82.7%). GPC3-positive patients were younger with higher frequencies of microvascular invasion and higher AFP levels than GPC3-negative patients. There was no significant difference in survival between GPC3-negative and GPC3-positive patients. Based on multivariate analysis, GPC3 expression was not a prognostic marker for post-operative survival. In South Korean HCC patients, GPC3 expression was more frequent in HCCs with aggressive features, but it was not an independent prognostic biomarker.
肝细胞癌(HCC)患者在根治性手术切除后通常总体生存期(OS)和无病生存期(DFS)较差。磷脂酰肌醇蛋白聚糖-3(GPC3)已被认为是术后生存的预后生物标志物。然而,这些研究中几乎没有纳入韩国患者。本研究旨在确定接受根治性手术切除的韩国HCC患者中GPC3的表达率、临床相关性及术后预后价值。收集了185例HCC患者手术切除的组织并制成组织微阵列(TMA),通过免疫组织化学对其进行GPC3染色。GPC3表达率与临床病理信息相关,并进行生存分析以评估GPC3的预后价值。153例患者(82.7%)存在GPC3表达。GPC3阳性患者比GPC3阴性患者更年轻,微血管侵犯频率更高,甲胎蛋白(AFP)水平更高。GPC3阴性和GPC3阳性患者的生存率无显著差异。基于多变量分析,GPC3表达不是术后生存的预后标志物。在韩国HCC患者中,具有侵袭性特征的HCC中GPC3表达更常见,但它不是独立的预后生物标志物。